Janux Therapeutics, Inc. (JANX)
NASDAQ:JANX
Want to see JANX full AI Analyst Report?
JANX Stock Chart & Stats
$15.82
-$2.71(-4.69%)
At close: 4:00 PM EST
$15.82
-$2.71(-4.69%)
Day’s Range― - ―
52-Week Range$12.12 - $35.34
Previous CloseN/A
Volume1.13M
Average Volume (3M)922.29K
Market Cap
$878.17M
Enterprise Value$847.92M
Total Cash (Recent Filing)$956.39M
Total Debt (Recent Filing)$21.57M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Aug 11, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding60,984,352
10 Day Avg. Volume834,841
30 Day Avg. Volume922,287
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)0.89
Price to Sales (P/S)85.51
P/FCF Ratio-10.27
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue39.23
Enterprise Value/Gross Profit72.45
Enterprise Value/Ebitda-6.35
Forecast
1Y Price Target
$39.79Price Target Upside151.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-1.89
Revenue Forecast (FY)$29.91M
Bulls Say, Bears Say
Bulls Say
Autoimmune Pipeline ExpansionInitiation of first-in-human dosing for JANX011 indicates meaningful expansion into autoimmune indications and could differentiate the company with an off-the-shelf CD19 bispecific approach.
Clinical Data ReadoutsA clinical update for JANX007 at a medical conference could reestablish investor confidence and act as a major catalyst if expanded data show durable benefit and a clear safety profile.
Platform Validation And PartnershipsA collaboration with a large pharmaceutical company validates the tumor-activated platform and bolsters the technology's commercial potential across oncology programs.
Bears Say
Analyst Sentiment And ValuationAnalyst downgrades to Neutral and lowered peak market assumptions reflect reduced valuation and highlight a lack of identifiable near-term stock-moving catalysts.
Competitive PressureA competitor's T-cell engager reported strong early responses with manageable safety, increasing competitive pressure and making it harder for JANX007 to capture market share.
Mixed Clinical ResultsMixed early clinical data for JANX007 showed weaker responses and biomarker results than prior updates, introducing uncertainty about efficacy and durability in broader patient groups.
Janux Therapeutics Inc News
JANX FAQ
What was Janux Therapeutics, Inc.’s price range in the past 12 months?
Janux Therapeutics, Inc. lowest stock price was $12.12 and its highest was $35.34 in the past 12 months.
What is Janux Therapeutics, Inc.’s market cap?
Janux Therapeutics, Inc.’s market cap is $878.17M.
When is Janux Therapeutics, Inc.’s upcoming earnings report date?
Janux Therapeutics, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 82 days.
How were Janux Therapeutics, Inc.’s earnings last quarter?
Janux Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.551 by $0.161.
Is Janux Therapeutics, Inc. overvalued?
According to Wall Street analysts Janux Therapeutics, Inc.’s price is currently Undervalued.
Does Janux Therapeutics, Inc. pay dividends?
Janux Therapeutics, Inc. does not currently pay dividends.
What is Janux Therapeutics, Inc.’s EPS estimate?
Janux Therapeutics, Inc.’s EPS estimate is -0.31.
How many shares outstanding does Janux Therapeutics, Inc. have?
Janux Therapeutics, Inc. has 60,984,352 shares outstanding.
What happened to Janux Therapeutics, Inc.’s price movement after its last earnings report?
Janux Therapeutics, Inc. reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.551. Following the earnings report the stock price went down -2.51%.
Which hedge fund is a major shareholder of Janux Therapeutics, Inc.?
Currently, no hedge funds are holding shares in JANX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Janux Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.79 (151.49% Upside)
$39.79 (151.49% Upside)
Blogger Sentiment
Bullish
JANX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 332.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $28.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.86%
12-Months-Change
Fundamentals
Return on Equity
-11.85%
Trailing 12-Months
Asset Growth
-2.15%
Trailing 12-Months
Company Description
Janux Therapeutics, Inc.
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
JANX Stock 12 Month Forecast
Average Price Target
$39.79
▲(151.49% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Vera Therapeutics
―
Biohaven Ltd.
―
Ownership Overview
19.65% Insiders
15.15% Mutual Funds
44.93% Other Institutional Investors
9.19% Public Companies and
Individual Investors